Focal neurolysis, or chemodenervation, has long been used as a management tool for spasticity. Local pharmacological therapies have traditionally included phenol and alcohol neurolysis. More recently botulinum toxin (BTX) chemodenervation has gained popularity for management of focal spasticity in a number of neurologic disorders, because of its ease of administration, good side effect profile and beneficial effects (Franciso et al. 2002; Kirazli et al. 1998; Simpson et al. 1996; Smith et al. 2000; Dolley et al. 1984).